Global Radiation Toxicity Treatment Market - 2023-2030

Overview

The Global Radiation Toxicity Treatment Market reached US$ 2.9 billion in 2022 and is expected to reach US$ 4.6 billion by 2030 growing with a CAGR of 6.1% during the forecast period 2023-2030. The radiation toxicity treatment market is driven by factors such as increasing cancer incidence, rising aging population and government initiatives. The health consequences of exposure to ionizing radiation constitutes radiation toxicity treatment. The method of treatment is determined by the degree of radiation exposure, the particular symptoms, and the seriousness of the problem.

Managing symptoms and preserving the patient's general health are the major priorities. This may involve dealing with concerns including nausea, vomiting, and diarrhea as well as managing pain and taking care of open wounds.The efficiency of interventions can be impacted by the interval between radiation exposure and the start of therapy. Early intervention may stop or lessen some effects.

The treatment options of a patient will be dependent on the accessibility of medical facilities, specialist therapies, drugs, and healthcare personnel. Radiation sensitivity varies among various tissues and organs. Treatment plans will be specifically designed to target the many problematic areas. New therapeutic approaches and interventions may be developed as a result of ongoing study on radiation toxicity and related therapies.

Market Dynamics

The Increasing Cancer Incidence are Driving the Global Radiation Toxicity Treatment Market Growth

The need for radiation therapy is driven by the rising incidence of cancer worldwide, which in turn supports the desire for efficient radiation toxicity treatments to manage the side effects. If incidence stays unchanged and population growth and aging follow current trends, there will be an estimated 28 million new cancer cases annually by 2040. This represents an increase of 54.9% from 2020, and it is anticipated that males will have a greater increase (60.6%) than girls (48.8%).

Alcohol intake, sleep deprivation, smoking, obesity, and consuming highly processed foods were all potential risk factors for early-onset cancer. Surprisingly, researchers discovered that youngsters are getting far less sleep now than they did decades ago, despite the fact that adult sleep length hasn't changed significantly over the years.

The Increasing Aging Population Boost The Global Radiation Toxicity Treatment Market Growth

In population cancer may develop with age and its treatment radiation toxicity comes. According to research, older adults (defined as those 65 and older) had an 11 times higher risk of developing cancer than younger people. The burden of cancer among the elderly will increase during the next 20 years due to the aging of the world population.

Age is a well-known risk factor for cancer, which could lead to an increase in the number of cancer diagnoses. The bulk of cancer diagnoses and cancer deaths occur in people over 65. A lot of preparation is required for this expanding public health concern. To provide a thorough approach to the requirements of elderly cancer patients and survivors, more work must be done in this area.

Challenges with Radiation Toxicity Treatment are Hampering the Global Radiation Toxicity Treatment Market Growth

Growth of the market may be hampered by a lack of knowledge about the advantages of radiation toxicity therapies among patients and medical professionals. The introduction of innovative items to the market may be slowed back by the lengthy and expensive regulatory approvals process for new radioprotective medications and treatments. Radiation toxicity treatments may be expensive to develop and market, which may limit patient access in some areas or within particular healthcare systems.

Segment Analysis

The global radiation toxicity treatment market is segmented based on product, indication, radiation type, end-user and region.

The Acute Radiation Syndrome Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The acute radiation syndrome segment accounted for the highest market stake accounting for approximately 46.2% of the radiation toxicity treatment market in 2022. Cardiovascular illness and cancer frequently co-occur. Cardiovascular toxicities can be caused by chemotherapy, radiation therapy, and other cancer treatments. Coronary artery disease (CAD), valvular heart disease (VHD), heart failure (HF), myocarditis, cardiomyopathies, arrhythmias, and acute and chronic pericardial syndromes may all be brought on by radiation treatment.

Cardiotoxicities brought on by radiation therapy are caused by a variety of processes. The interval between radiation therapy exposure and the onset of cardiac toxicities, as well as the radiation dose to which the heart is exposed, are additional crucial factors. While some cardiac toxicities, such as pericardial effusion or acute pericarditis, arrhythmic events, and conduction abnormalities, can manifest right away after the start of radiotherapies, others, like coronary artery disease, valvular heart disease, chronic pericardial syndromes, and constriction, can take years to manifest.

Geographical Penetration

North America Holds a Dominant Position in the Global Radiation Toxicity Treatment Market

North America is holding around 38.8% of the total market share in 2022. As of October 2022, the acute radiation syndrome (ARS)-related blood cell damage that Nplate from Amgen treats in both children and adults will cost the U.S. Department of Health and Human Services (HHS) an undisclosed amount of money to lock up. When a person's body is subjected to a high dose of penetrating radiation, which is capable of "reaching internal organs in a matter of seconds,", is also known as radiation sickness.

Competitive Landscape

The major global players in the market include: Amgen, Jubilant Pharma Limited, Tanner Pharma Group, Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG, Recipharm AB, Mission Pharmacal Company, Partner Therapeutics, Inc., Novartis AG, Mylan NV, and Coherus Biosciences Inc. among others.

COVID-19 Impact Analysis

Russia-Ukraine Conflict Analysis

The Russia-Ukraine war may affect the radiation toxicity treatment market due to a lack of facilities being impacted during times of geopolitical instability and economic uncertainty. Resources and attention may be diverted away from research and development projects in the healthcare industry, particularly radiation toxicity therapy, during times of conflict or war.

Artificial Intelligence Analysis:

Artificial intelligence (AI) is increasingly being used in the radiation toxicity treatment market to improve various aspects of data analysis. Radiomics is the study of quantitative features extracted and analyzed from medical pictures. Based on the particular characteristics of a patient's anatomy, AI-driven radiomics may forecast the likelihood of radiation damage. This knowledge can direct medical decisions and assist practitioners in identifying patients who could be more vulnerable to toxicity.

By Treatment

• Colony Stimulating Factors
• Potassium Iodide
• Prussian Blue
• Diethylenetriamine Pentaacetic Acid
• Others

By Indication

• Acute Radiation Syndrome
  • Bone Marrow Syndrome
  • Gastrointestinal Syndrome
  • Cardiovascular syndrome

• Chronic Radiation Syndrome

By Radiation Type

• Ionizing Radiation
  • Alpha Radiation
  • Beta Radiation
  • Gamma Radiation

• Non-ionizing Radiation

By End-user

• Hospitals
• Specialty Clinics
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• In March 2023, Coherus BioSciences, Inc. reported that The U.S. Food and Drug Administration approved UDENYCA (pegfilgrastim-cbqv), a biosimilar pegfilgrastim that is given the day after chemotherapy to lessen the likelihood of infection as seen by febrile neutropenia. The UDENYCA autoinjector has a simple, user-friendly design that makes it suitable for usage in both in-office and at-home care settings. It is indicated to patients who receive radiation doses that are myelosuppressive in nature are more likely to survive (Hematopoietic Subsyndrome of Acute Radiation Syndrome).

Why Purchase the Report?

• To visualize the global radiation toxicity treatment market segmentation based on the product, indication, radiation type, end-user and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of radiation toxicity treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of critical products of all the major players.

The global radiation toxicity treatment market report would provide approximately 69 tables, 69 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies